COVID-19 has played a havoc with the lives of cancer patients. Because often because of the COVID-19 pandemic scare patients are not coming to the hospital for their therapies whether it is chemotherapy or radio ligand therapy. Now specifically for Lutetium PSMA Therapy the entire philosophy or the science behind giving multiple fractionated doses of Lu PSMA at intervals of about 6-8 weeks, is to give repeated dosage of insult to the tumour, now if these doses are not given at frequent intervals or at the designated intervals, the tumour cells begin to find ways of becoming refractory to this tumour and that really damages the response rate of Lu PSMA to this therapy. So unless these therapies are given in the adequate dosages at adequate intervals the overall response rate are the overall outcomes would be much poorer.